Recruiting
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants - CV028-005
Opdateret:
20 december, 2023
|
ClinicalTrials.gov
Fase
Køn
Aldersinterval
Beliggenhed(er)
Recruiting
Inclusion Criteria: - Has stable primary dilated cardiomyopathy due to either MYH7 or TTN variant - Has adequate acoustic windows for echocardiography - Maximum of 3 family members with same variant can be enrolled Exclusion Criteria: - Significant structural cardiac abnormalities including valvar dysfunction on Screening transthoracic echo(s) - A pathogenic variant implicated in DCM of another gene other than MYH7 or TTN - Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, afterload reduction, or diuretics) - Presence of protocol specified laboratory abnormalities at Screening - Recent acute coronary syndrome or angina pectoris (<90 days) - Recent hospitalization for heart failure (<90 days)
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001